ArQule, Camitro Corp., SignalGene deal

ARQL will acquire Camitro for 3.4 million shares, or about $95 million. The deal will combine Camitro's in silico predictive absorption, distribution, metabolism, elimination and toxicity (ADMET) modeling platform with ARQL's small molecule design and high throughput, automated chemistry expertise. ARQL also may pay Camitro shareholders $10 million in cash at closing, depending on the deal's valuation. ...